Drug Profile
Canagliflozin/teneligliptin - Mitsubishi Tanabe Pharma Corporation
Alternative Names: CANALIA; MT-2412; TA-7284/MP-513Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Mitsubishi Tanabe Pharma Corporation
- Class Antihyperglycaemics; Glucosides; Ketones; Piperazines; Pyrazoles; Small molecules; Thiazolidines; Thiophenes
- Mechanism of Action Dipeptidyl peptidase 4 inhibitors; Sodium-glucose transporter 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Type 2 diabetes mellitus